Atlas Trials

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Clinical trial NCT03941860 · COMPLETED

Trial details

NCT number
NCT03941860
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2022-02-16
Primary completion
2023-08-06
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.